AR and neoplasm: Preclinical data indicate that the combination of enzalutamide (an AR inhibitor) with copper ionophores reduces tumor growth by specifically targeting AR-V7-positive cells.8,18 This approach leverages the AR-copper crosstalk to enhance therapeutic efficacy, warranting further clinical exploration.